Research Grade Diridavumab
Product Sizes
1 mg
£506.00
DVV03801-1MG
5 mg
£1169.00
DVV03801-5MG
25 mg
£2865.00
DVV03801-25MG
About this Product
- SKU:
- DVV03801
- Additional Names:
- CR-6261, CR6261, CAS: 1393659-46-5
- Buffer:
- 0.01M PBS, pH 7.4.
- translate.label.attr.clone:
- Diridavumab
- Clonality:
- Recombinant Monoclonal
- Concentration:
- 1.41 mg/ml
- Extra Details:
- Diridavumab, the alternative names CR6261, is a human monoclonal antibody direct against influenza A hemagglutinin. The CR6261 antibody was first discovered by the Scripps Institute and Crucell, a dutch biopharmaceutical company, and later developed by Janssen Pharmaceutical Companies of Johnson & Johnson under the trade name diridavumab. Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants).
- Host:
- Human
- Immunogen:
- HA/Hemagglutinin
- Isotype:
- IgG1, lambda
- Physical State:
- Liquid
- Purity:
- >95%
- Purification:
- Protein A/G purified from cell culture supernatant.
- Reactivities:
- Virus
- Shipping Conditions:
- Blue Ice
- Source:
- XtenCHO
- Storage Conditions:
- -20[o]C Avoid freeze/thaw cycles., 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Supplier:
- AntibodySystem
- Type:
- Antibody: Recombinant Antibodies
- Manufacturer's Data Sheet:633.html
